https://www.openbell.ai/ 2026-10-31T13:43:23.188Z hourly 1.0 https://www.openbell.ai/support 2026-10-31T13:43:23.188Z monthly 0.7 https://www.openbell.ai/privacy 2026-10-31T13:43:23.188Z monthly 0.5 https://www.openbell.ai/terms 2026-10-31T13:43:23.188Z monthly 0.5 https://www.openbell.ai/feed.json 2026-10-31T13:43:23.188Z hourly 0.8 https://www.openbell.ai/news/BOLT:1793451965000 2026-10-31T13:06:05.000Z daily 0.9 https://cdn.brandfetch.io/BOLT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bolt Biotherapeutics Completes Merger with Prana Therapies Bolt Biotherapeutics completed its acquisition of Prana Therapies through a sign-and-close reverse merger, alongside a $120 million financing. On a fully diluted basis, Prana equity holders own 51.7% of the combined company, private placement investors 41.4%, and Bolt equity holders 6.9%. Bolt is refocusing its pipeline and expects to move two additional undisclosed programs toward IND-enabling development by the second half of 2027. https://www.openbell.ai/news/COMP:1793451929000 2026-10-31T13:05:29.000Z daily 0.9 https://cdn.brandfetch.io/COMP/w/400/h/400?c=1idopYfmtR7ZKg8QMud Uniserve Communications Corporation Announces First Quarter Fiscal 2027 Financial Results Uniserve Communications reported first-quarter fiscal 2027 revenue of $2.95 million for the period ended August 31, 2026, up from $2.122 million a year earlier. Its net loss widened to $1.068 million from $264,000. The company said it is pursuing operational efficiencies, recurring-revenue growth, and improved customer value to strengthen operating results in fiscal 2027. https://www.openbell.ai/news/INO:1793451893000 2026-10-31T13:04:53.000Z daily 0.9 https://cdn.brandfetch.io/INO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Inovio Receives FDA Accelerated Approval for VOCERYQ to Treat Recurrent Respiratory Papillomatosis Inovio Pharmaceuticals said the FDA granted accelerated approval to VOCERYQ, formerly INO-3107, a plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis that targets HPV-6 and HPV-11 and is intended to reduce surgery frequency. It is the first plasmid DNA-based immunotherapy approved in the United States and, according to Inovio, validates its CELLECTRA delivery platform. The company expects to begin taking orders and shipping in about 60 days, with a full commercial launch anticipated in the first quarter of 2027. Approval requires Inovio to conduct a post-marketing confirmatory study. https://www.openbell.ai/news/KDK:1793451871000 2026-10-31T13:04:31.000Z daily 0.9 https://cdn.brandfetch.io/KDK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Kodiak AI Reaches 99% Autonomy Readiness Measure, On Track for Year-End Driverless Launch Kodiak AI reported that its Autonomy Readiness Measure for long-haul driverless operations reached 99%, advancing its goal of launching driverless commercial service by the end of 2026. As of the end of the second quarter of 2026, its technology was deployed in 35 driverless trucks operated by customer Atlas Energy Solutions, building on Kodiak’s Permian Basin experience. The company is pursuing commercialization of its hardware-agnostic virtual driver technology through its Driver-as-a-Service model; the article did not report financial results or a stock-price move. https://www.openbell.ai/news/FBIZ:1793451831000 2026-10-31T13:03:51.000Z daily 0.9 https://cdn.brandfetch.io/FBIZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud First Business Financial Services Reports Third-Quarter 2026 Financial Results First Business Financial Services reported third-quarter 2026 revenue of $47.5 million, up 6.7% year over year, and net income available to common shareholders of $16.4 million, up 15.4%; diluted EPS rose to $1.95 from $1.70. Results benefited from loan and deposit growth, a wider net interest margin, and lower expenses. Loans increased 11.9% year to date, led by commercial real estate and commercial and industrial lending, while average core deposits grew 17.6%. The company repurchased 41,058 shares for approximately $2.9 million during the quarter. https://www.openbell.ai/news/VREX:1793451828000 2026-10-31T13:03:48.000Z daily 0.9 https://cdn.brandfetch.io/VREX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bundeskartellamt Merger Control Filing Regarding Teledyne Technologies and Varex Imaging Germany’s Bundeskartellamt listed a merger-control proceeding on October 22, 2026, concerning Teledyne Technologies’ proposed acquisition of all shares and sole control of Varex Imaging. The filing is a procedural step in the regulatory review of the $1.1 billion deal, announced in August 2026. Closing remains subject to customary conditions, including further regulatory clearances and approval by Varex stockholders. https://www.openbell.ai/news/ATEC:1793451800000 2026-10-31T13:03:20.000Z daily 0.9 https://cdn.brandfetch.io/ATEC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Alphatec Holdings, Inc. Reports Third Quarter 2026 Financial Results and Revises Full-Year Guidance Alphatec Holdings reported third-quarter 2026 revenue of $221 million, below analysts’ $225 million estimate, and adjusted earnings of 9 cents per share versus the 10-cent consensus. Management cited weaker cross-selling, including reduced use of high-margin biologics in spinal fusion procedures, as well as industry softness and lower-than-expected mid-to-lower back surgery volumes. The company lowered its 2026 revenue guidance to approximately $862 million from $882 million.